Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Aimisen regarding its equity changes, shareholder situation, and business operations as part of its application for listing on the Hong Kong Stock Exchange [1][2]. Group 1: Equity Changes - Aimisen is required to clarify the basis for pricing in its past capital increases and share transfers, including whether there are any unpaid capital contributions or issues with the method of contribution [2]. - The company must explain the reasons behind a 0 yuan transfer of shares by two shareholders in June 2016, which resulted in a change of control, and whether this involved any shareholding arrangements [2]. - Historical instances of shareholding arrangements must be verified according to regulatory guidelines [2]. Group 2: Shareholder Situation - Aimisen needs to justify the reasonableness of the share prices for new shareholders over the past 12 months and confirm whether there are any issues of interest transfer [2]. - The company must disclose whether any of its significant shareholders, such as Guangzhou Kaipu and Suzhou Jinhui, are prohibited from holding shares under relevant laws [2]. - Clarification is required regarding the identification of state-owned shareholders related to Gaoke Medical and the basis for this identification [2]. Group 3: Business Operations - Aimisen must detail its business scope, including medical research, cell technology development, and gene diagnosis and treatment, and confirm whether it has the necessary licenses and permits [3]. - The company is required to disclose its related transactions with Kaipu Biology, Guangdong Kaipu Biology, and Wuhan Ainuo Medical Laboratory, as well as its independence in personnel, business, assets, and finances [3]. Group 4: Listing and Full Circulation - Aimisen needs to outline its plans for share subdivision and whether this will affect the number of shares issued in the upcoming listing [3]. - The company must ensure that the information in its filing materials aligns with the prospectus regarding the issuance plan [3]. - It is necessary to confirm whether the shares held by shareholders participating in the "full circulation" are subject to any pledges, freezes, or other rights issues [3]. Group 5: Company Overview - Aimisen is a leading early cancer detection company focusing on high-incidence and high-mortality cancers, having developed early cancer detection technology based on methylation [4]. - The company has two core products: Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer, with Aixin Gan achieving a sensitivity of 92.33% and specificity of 93.35% in liver cancer detection [4]. - Aiguang Le allows for non-invasive detection of urinary tract cancer using just 1 milliliter of urine, significantly improving efficiency and convenience compared to traditional methods [4].
新股消息 | 艾米森拟港股上市 中国证监会要求补充说明股权变动等事项
Zhi Tong Cai Jing·2025-11-14 12:12